^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Jemperli (dostarlimab-gxly) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
09/10/2021
Excerpt:
Systemic therapy for advanced or metastatic disease...dostarlimab-gxly added as a subsequent therapy option for dMMR/MSI-H...
Excerpt:
JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced...solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
Source:
Title:
Phase 2 Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Estudio de fase II de dostarlimab en pacientes con cáncer de recto dMMR/MSI-H localmente avanzado no tratado previamente
Excerpt:
...Inclusion criteria (Prescreening Period)- A Prescreening Period will only be available at sites/countries where local dMMR/MSI-H testing is not available. ...
Trial ID:
Source:
Title:
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Excerpt:
...- Has a tumor demonstrating the presence of either dMMR status or MSI-H...
Trial ID:
More C2 evidence
Source:
Title:
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
Excerpt:
...- Participant has a tumor which can be categorized as dMMR or MSI-H by local or central assessment...
Trial ID:
Less C2 evidence
Source:
Title:
Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: A post-hoc subgroup analysis of patients with colorectal cancer.
Published date:
01/18/2022
Excerpt:
Confirmed ORR by BICR per RECIST v1.1 in pts with dMMR CRC was 36.2% (95% CI, 25.0%–48.7%). There were 3 complete responses and 22 partial responses....Dostarlimab demonstrated durable clinically meaningful antitumor activity in pts with dMMR CRC, which was consistent with that seen in patients with dMMR non-CRC solid tumors.
DOI:
10.1200/JCO.2022.40.4_suppl.201
Trial ID:
Source:
Title:
Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
Published date:
01/11/2021
Excerpt:
Of the 106 pts, 99 (93.4%) had GI tumors. Confirmed ORR in dMMR pts was 38.7% (95% CI: 29.4, 48.6), with a complete response rate of 7.5%. ORR was consistent across tumor type (Table). Dostarlimab demonstrated durable antitumor activity in a cohort of dMMR solid tumor pts, the majority of whom had GI cancers.
Trial ID:
